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The long terminal repeat (LTR) region of leukemia viruses plays a critical role in tissue tropism and pathogenic potential of the viruses. We
have previously reported that U3-LTR from Moloney murine and feline leukemia viruses (Mo-MuLV and FeLV) upregulates specific cellular
genes in trans in an integration-independent way. The U3-LTR region necessary for this action does not encode a protein but instead makes a
specific RNA transcript. Because several cellular genes transactivated by the U3-LTR can also be activated by NFnB, and because the
antiapoptotic and growth promoting activities of NFnB have been implicated in leukemogenesis, we investigated whether FeLV U3-LTR can
activate NFnB signaling. Here, we demonstrate that FeLV U3-LTR indeed upregulates the NFnB signaling pathway via activation of Ras-Raf-InB
kinase (IKK) and degradation of InB. LTR-mediated transcriptional activation of genes did not require new protein synthesis suggesting an active
role of the LTR transcript in the process. Using Toll-like receptor (TLR) deficient HEK293 cells and PKR/ mouse embryo fibroblasts, we
further demonstrate that although dsRNA-activated protein kinase R (PKR) is not necessary, TLR3 is required for the activation of NFnB by the
LTR. Our study thus demonstrates involvement of a TLR3-dependent but PKR-independent dsRNA-mediated signaling pathway for NFnB
activation and thus provides a new mechanistic explanation of LTR-mediated cellular gene transactivation.
D 2005 Elsevier Inc. All rights reserved.Keywords: Leukemia virus; LTR; Transactivation; NFnB; TLR3Introduction
The long terminal repeat (LTR) region of nontransforming
retroviruses such as leukemia viruses plays a critical role in their
replication and pathogenesis (DesGroseillers and Jolicoeur,
1984; Fan, 1990; Lenz et al., 1984). These repeat regions (U3-
R-U5) are generated during reverse transcription of the viral
genome and are present at both ends of the proviral sequence
integrated in the host genome. The U3-LTR region of leukemia
viruses contains multiple transcription factor binding sites that
provide tissue-specific expression capacity to the virus (Gole-
mis et al., 1989; Short et al., 1987). Further, these transcription
factor-binding sites can also enhance the transcriptional activity
of cellular genes adjacent to the site of integration of these0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: sajal@bu.edu (S.K. Ghosh).viruses (Hayward et al., 1981). Activation of a proto-oncogene
adjacent to the site of integration can result in abnormal
expression of the gene and may ultimately lead to tumorigen-
esis. Insertional activation of proto-oncogenes c-myc, pim-1,
pvt-1, flvi-2, int-1/wnt-1 and others have been reported in
various leukemia virus pathogenesis (Fan, 1997; Morrison et
al., 1995; Selten et al., 1985).
Long before tumor development, a state of preleukemic
hyperplasia is seen in the leukemia virus infected animals. It
has been suggested that this preleukemic hyperplasia provides
more cells susceptible to virus infection and therefore increases
the chance of insertional activation of proto-oncogenes (Bright-
man et al., 1990; Davis et al., 1987). Interestingly, insertion of
polyoma virus transcriptional enhancer element PyF101 into
the Moloney murine leukemia virus (Mo-MuLV) U3-LTR
greatly reduces the preleukemic hyperplasia and the leukemo-
genic potential of the virus, but does not interfere with normal6) 390 – 403
www.e
A.L. Abujamra et al. / Virology 345 (2006) 390–403 391replication of the virus (Brightman et al., 1991, 1993; Davis et
al., 1985). This finding suggested that the LTR may have some
role in the induction of preleukemic hyperplasia in addition to
its activity as an enhancer element. Other studies demonstrated
that transient or stable expression of the U3-LTR region of Mo-
MuLVor feline leukemia virus (FeLV) in fibroblasts of murine
or feline origin, as well as in human lymphoid cell lines,
induces expression of specific cellular genes, such as collage-
nase IV, monocyte chemotactic protein 1 (MCP-1), c-jun and
MHC class I (Faller et al., 1997a, 1997b; Ghosh and Faller,
1999; Koka et al., 1991; Wilson et al., 1987). Upregulation of
these genes occurs at the level of transcription and is
independent of the physical location of the LTR or the
responding cellular genes. The LTR from endogenous FeLV,
however, which is nonpathogenic, does not possess this
transactivational activity (Ghosh et al., 2000). Whether the
cellular gene transactivational activity of the LTR is necessary
for preleukemic hyperplasia has not been determined.
The mechanism of LTR-mediated transactivation of cellular
genes has not been elucidated. We have previously reported
that only the U3 region of the LTR is necessary for this
transactivational activity and, in case of FeLV, it can be as
small as 210 bp (Choi and Faller, 1995; Ghosh and Faller,
1999; Ghosh et al., 2000). The U3-LTR region sufficient for
gene transactivational activity does not contain a readable
protein-coding frame. A specific RNA transcript for this region
has been consistently detected in cells expressing only the U3-
LTR as well as cells infected with the full-length virus (Ghosh
and Faller, 1999). We have also demonstrated that LTR from
nonpathogenic endogenous FeLV, which cannot transactivate
cellular genes, does not make LTR-specific transcript (Ghosh et
al., 2000). Since the U3-LTR is unable to make a protein
product, it is likely that the RNA transcript generated acts as a
mediator of cellular gene transactivation.
Double-stranded RNA (dsRNA) is a strong inducer of
several signal transduction pathways including activation of the
transcription factor NFnB (Geiss et al., 2001; Ghosh et al.,
1998; Siebenlist et al., 1994). NFnB is intimately associated
with cellular defense mechanisms as it is activated by a variety
of inflammatory cytokines, growth factors and stress inducing
agents (Karin and Ben-Neriah, 2000; Kopp and Ghosh, 1995).
Recent evidences also suggest that NFnB plays an important
role in cell survival and antiapoptotic responses (Baldwin,
2001; Yamamoto and Gaynor, 2001). In nonstimulated cells,
NFnB exists as a cytoplasmic heterodimeric complex com-
posed mainly of p50 and RelA proteins bound to inhibitory
proteins of InB family. Upon stimulation, the InB protein is
phosphorylated and degraded in the proteasome allowing free
NFnB heterodimer to migrate to the nucleus where it binds to
its cognate binding sites on the promoters of various target
genes and enhances their expression. Because of the diverse
range of genes that NFnB can modulate, it also has been an
important target molecule for many viruses including tumor-
igenic viruses, such as Epstein–Barr virus (EBV), hepatitis C
virus (HCV), human T-lymphotropic virus (HTLV) and also
human immunodeficiency virus (HIV) (Hiscott et al., 2001;
Santoro et al., 2003). Although different viruses use differentstrategies to control NFnB, many of them converge to the
activation of InB kinase (IKK). Double stranded RNA-
dependent protein kinase R (PKR) and some members of the
Toll-like receptor (TLR) family (such as TLR3) have been
shown to act as an intermediate in the activation of the NFnB
pathway by RNA (Alexopoulou et al., 2001; Williams, 1997,
2001).
The ability of the LTR to mediate cellular gene transactiva-
tion through the production of an RNA transcript and the
observation that many of the cellular genes transactivated by
the LTR are known to be NFnB responsive indicated that LTR
might activate NFnB signaling. In this study, we investigated
such a possibility and report that leukemia virus LTR activates
NFnB signaling pathway. We also investigated the role of PKR
and RNA-activated TLRs in this process. Using cell lines
deficient in either PKR or TLRs, we found that although PKR
is dispensable, TLR3 is necessary for LTR-mediated activation
of NFnB. Our results thus provide a new insight into the
mechanism of leukemia virus LTR-mediated cellular gene
activation.
Results
U3-LTR activates NFjB-dependent gene expression
Numerous reports have demonstrated that the leukemia
virus LTR directly influences propagation of the virus through
the transcription factor binding sites they contain. There are
recent indications that the LTR may also play a role in target
lymphocyte proliferation during preleukemic hyperplasia. Our
previous studies demonstrated that the LTR can upregulate
expression of specific cellular genes, some of which can also
be activated by NFnB, through the generation of a noncoding
RNA transcript (Ghosh and Faller, 1999; Ghosh et al., 2000).
RNA secondary structure analysis predicted that the putative
LTR transcript possessed strong secondary structure (data not
shown). Since dsRNA is a strong activator of NFnB, we
examined whether NFnB signaling is activated in cells that are
expressing LTR. We cotransfected NFnB-dependent reporter
plasmid NFBCO-CAT with FeLV U3-LTR construct 61E-LTR
into Balb-3T3 cells. The NFBCO-CAT construct contains two
NFnB binding sites from h-interferon gene adjacent to a
minimal h-globin promoter (Richardson and Gilmore, 1991).
We compared upregulation of this NFBCO-CAT reporter by
the 61E-LTR along with other promoter-reporters we have
previously shown to be transactivated by the LTR. In Fig. 1A,
we show that the 61E-LTR can activate expression of NFBCO-
CAT reporter up to 22-fold. In parallel, we show that the LTR
construct can induce expression of reporters containing
promoters for genes such as collagenase IV, MCP-1, MHC-I,
but not IL-6, thus corroborating our previously published
report (Ghosh and Faller, 1999). We next tested whether
activation of NFnB-dependent gene expression by the LTR was
directly related to increased DNA-binding activity of NFnB
protein. To address this issue, in transient transfection assays,
we used another reporter construct OBCO-CAT, which is the
same as the NFnB-dependent reporter NFBCO-CAT except
Fig. 1. Activation of NFnB-dependent gene expression by the LTR. (A) Analysis of transactivational activity of the 61E-LTR towards CAT-reporters with promoters
from different genes. Balb-3T3 cells were cotransfected in 100 mm plates with 7.5 Ag of 61E-LTR or the vector plasmid pTZ19 and 7.5 Ag of various CAT-reporter
constructs by DEAE-dextran method and were harvested 48 h post-transfection for reporter assays. This experiment was performed three times and a representative
chromatogram is presented. For quantitation purpose, individual spots on the chromatogram were collected by scraping and radioactivity was measured by liquid
scintillation counting. Fold-induction for any particular CAT construct was expressed as the ratio of acetylated 14C-chloramphenicol generated for that construct by the
LTR to that generated by the vector. (B) Requirement of NFnB binding-site in the reporter for activation by the LTR. Two different CAT-reporter plasmids, with or
without NFnB binding sites in the promoter (NFBCO-CAT or OBCO-CAT, respectively) were cotransfected separately with 61E-LTR or pTZ19 plasmid in Balb-3T3
cells and CAT assays were performed. To determine dose dependence, 2.5, 5.0 or 7.5 Ag of 61E-LTR was transfected. One representative chromatogram and fold-
induction values are presented. (C) Analysis of transactivational activity of 61E-LTR towards two different NFnB-dependent luciferase reporter constructs. Six-well
plates of Balb-3T3 cells were cotransfected with 61E-LTR or pTZ19 (300 ng) and 3XKB-luc (100 ng) or PBIIX-Luc reporter (100 or 250 ng) by lipofectamine plus
method and harvested 48 h post-transfection for luciferase assays. Total amount of plasmid transfected in each well in both transfection methods was maintained equal
using pTZ19 vector plasmid.
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Gilmore, 1991). In Fig. 1B, we demonstrate that 61E-LTR can
activate NFBCO-CAT but not the NFnB binding site-deleted
reporter OBCO-CAT suggesting that these sites are necessary
for NFnB activation by the LTR. This activation is dose-
dependent as the fold induction of NFBCO-CAT increases with
increasing amount of 61E-LTR.
We next tested whether LTR can act on other NFnB-
dependent reporter constructs. We used two luciferase reporter
constructs, 3XKB-Luc (containing three copies of MHC class I
nB element upstream of a minimal c-fos promoter) and PBIIX-
luc (containing two copies of immunoglobulin light chain nB
element upstream of a minimal c-fos promoter) (Kopp and
Ghosh, 1994; Mitchell and Sugden, 1995). As shown in Fig.
1C, both these reporters were also strongly induced by 61E-
LTR (7–10-fold). It may be noted, however, that the basal
activity with PBIIX-luc reporter was significantly lower and
higher amounts of reporter plasmid than that of the 3XKB-luc
reporter were necessary to achieve comparable basal activity.
LTR enhances nuclear translocation of p65
We determined whether upregulation of NFnB-dependent
gene expression by the LTR was due to the increase of NFnBprotein in the nucleus. We measured the RelA protein (p65,
most common member of NFnB family of proteins) level in the
nucleus following expression of LTR. Nuclear extracts were
prepared from Balb-3T3 cells at multiple time points following
transfection with 61E-LTR or vector plasmid pTZ and were
analyzed for the p65/RelA protein by Western immunoblotting.
The level of common nuclear protein PCNA in these samples
was tested for sample loading control. Fig. 2A demonstrates
that p65/RelA protein level in LTR transfected cells increased
up to 2.2 times compared to pTZ vector transfected cells.
Transfection efficiency in these experiments was approximate-
ly 25%. The increase in p65 level could be seen within 2 h post-
transfection, reached a peak by 4 h and decreased gradually
over time. Transient increase of NFnB level of this nature
following virus infection has been previously reported with
vesicular stomatitis virus (VSV) and measles virus (MeV)
(Boulares et al., 1996; Donze et al., 2004; Helin et al., 2001).
The p65 level in pTZ vector transfected cells increased
insignificantly during the course of the study. These results
show that expression of LTR increased the level of p65/RelA
protein in the nucleus.
To test whether NFnB activation by the LTR indeed affects
expression of endogenous NFnB-dependent genes, we tested
the level of two genes, cyclin D1 and Bcl-2, in 61E-LTR
Fig. 3. Full length FeLV activates NFnB in an LTR-dependent manner. (A)
Analysis of NFnB activation by full-length and U3-LTR constructs from FeLV
and Mo-MuLV. Balb-3T3 cells were cotransfected with 7.5 Ag of NFBCO-CAT
reporter and 7.5 Ag of 61E-LTR (FeLV U3-LTR) or GMNX (Mo-MuLV U3-
LTR) or 61E (full-length FeLV) or Mov9 (full-length Mo-MuLV) or pTZ19
vector plasmid by DEAE-dextran method. Cells were harvested 48 h post-
transfection for CAT assays as described in Fig. 1. Similar results were obtained
in three independent experiments and the fold-induction values for the
presented chromatogram are indicated. (B) Analysis of NFnB activation by
the full-length FeLV containing mutation in the U3-LTR. Balb-3T3 cells were
cotransfected with 100 ng of 3XKB-luc reporter and 300 ng of either wild-type
or mutant FeLV U3-LTR constructs (61E-LTR or EDD2, respectively), or wild-
type or mutant full-length FeLV constructs (61E or 61E-Mut, respectively).
Cells were harvested 48 h post-transfection for luciferase assays as in Fig. 1.
Fig. 2. Translocation of p65 and expression of endogenous NFnB-dependent
genes by the LTR. (A) Analysis of nuclear p65 following expression of LTR.
Nuclear extracts were prepared from Balb-3T3 cells transfected with 61E-LTR
or pTZ19 by lipofectamine method at indicated time post-transfection. The time
denotes period after the initial 3 h incubation with DNA and lipofectamine.
Twenty micrograms of protein for each sample was separated in 10% SDS-
PAGE and analyzed for p65 or PCNA by Western immunoblotting. Band
intensities were determined directly on the film using LabWorks Image
Analysis Program (UVP Inc, Upland, CA). Fold inductions were calculated
after the band intensities were normalized for equal PCNA loading. (B)
Activation of endogenous cyclin D1 and Bcl-2 protein. Twenty micrograms of
whole cell lysates from Balb-3T3 cells transfected with either 61E-LTR or
pTZ19 vector was analyzed for cyclin D1 or Bcl-2 level by Western
immunoblotting. Lysates were prepared 40 h after transfection. Same blots
were further analyzed for h-actin protein following stripping of the antibodies
used in first immunoblotting.
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G1 phase and Bcl-2 acts as an antiapoptotic protein, both of
which are regulated by NFnB (Guttridge et al., 1999; Wang et
al., 1998). As shown in Fig. 2B, both cyclin D1 and Bcl-2
levels were increased significantly in LTR expressing cells over
backbone vector expressing cells. This result therefore, clearly
demonstrates that NFnB activation by the LTR leads to
upregulation of endogenous NFnB-dependent genes.
Full-length FeLV also activates NFjB
We tested whether LTR would activate NFnB in the context
of full-length virus. To address this issue, we first tested
whether full-length FeLV or MuLV could activate NFnB. We
cotransfected Balb-3T3 cells with NFBCO-CAT and either
61E-LTR or the full-length FeLV clone 61E and determined
NFnB activation by CAT assay. As shown in Fig. 3A, NFBCO-
CAT was activated up to 5.7-fold by the 61E. We also tested
NFnB activation by the U3-LTR construct and full-length cloneof Mo-MuLV (GMNX and Mov9, respectively). The NFBCO-
CAT reporter expression was activated up to a 29.1- and 9.4-
fold by the U3-LTR and full-length Mo-MuLV constructs,
respectively. Our finding thus corroborated previous observa-
tion that full-length Mo-MuLVactivates NFnB-dependent gene
expression (Pak and Faller, 1996). It is noteworthy that the
fold-induction of NFnB activation by the LTR in the context of
full-length virus was several-fold lower than that with the
isolated LTR. This effect is due to lower net LTR copy number
per absolute amount of DNA transfected and is consistent with
our previous publication (Ghosh and Faller, 1999). Next, to
determine if the U3-LTR is the responsible factor in full-length
virus for NFnB activation, we used a mutant FeLV U3-LTR
construct EDD2, which has an 8 base substitution mutation.
We also used a mutant full-length molecular clone of FeLV,
61E-Mut, which has EDD2-specific mutations in both of its
U3-LTRs. We have previously demonstrated that this mutant
virus replicates with wild-type kinetics yet cannot transactivate
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jamra et al., 2003). As shown in Fig. 3B, both the EDD2 and
the 61E-Mut were unable to activate NFnB-dependent lucifer-
ase reporter gene expression in transient transfection experi-
ment. This result demonstrated that U3-LTR portion of the full-
length FeLV is responsible for activation of NFnB-dependent
gene expression by the virus.
Proteasomal degradation of the inhibitory protein IkB is
necessary for NFjB activation by the LTR
Activation of NFnB-dependent gene expression primarily
depends on phosphorylation of inhibitory protein InB followed
by its proteasomal degradation in the cytoplasm and subse-
quent translocation of free NFnB heterodimer to the nucleus.
To determine whether proteasomal activity is necessary for the
activation of NFnB-dependent gene expression by the LTR, we
used the drug lactacystin that inhibits chymotrypsin- and
trypsin-like activities of proteasome (Dick et al., 1997). InFig. 4. Activation of NFnB by the LTR require proteasomal activity, phosphorylation
mediated activation of NFnB. Balb-3T3 cells were cotransfected with 100 ng 3XKB-lu
plus method. Lactacystin (5AM) or DMSO solvent control was added on to the c
transfection for luciferase assay. (B) Induction of InB-a degradation by the LTR. Balb
cytoplasmic extracts were prepared at indicated time period and analyzed for IkB-a by
of expression of super repressor dn-InB. Balb-3T3 cells were cotransfected with 10
plasmid (50 ng, 100 ng or 200 ng) by lipofectamine plus method as indicated in Fig.
inhibition of InB-kinase (IKK) activity. Balb-3T3 cells were cotransfected with 3XKB
form of IKK subunits (dn-IKK1 and dn-IKK2, 300 ng) as appropriate and processedtransient transfection experiments with 61E-LTR and NFnB-
dependent luciferase reporter 3XKB-luc, we tested the effect of
5 AM Lactacystin on reporter activity. As shown in Fig. 4A,
lactacystin, but not the DMSO solvent, inhibited induction of
luciferase reporter by the LTR significantly by 24 h post-
transfection. As a control, we tested upregulation of the same
reporter by p65/RelA expression plasmid and the effect of
lactacystin on it. Because proteasomal activity is not necessary
for p65/RelA-mediated upregulation of 3XKB-Luc, as
expected, similar concentrations of lactacystin did not affect
reporter activation. This result demonstrated that active
proteasome function is necessary for NFnB activation by the
LTR.
To determine whether NFnB activation by the LTR actually
leads to degradation of the inhibitory protein InB, we analyzed
cytoplasmic InB-a level over time in 61E-LTR transfected
cells. As shown in Fig. 4B, InB-a level decreased within 1
h after transfection, reached a minimum level within 2–3 h and
went back to steady state level thereafter. This trend was veryand degradation of InB. (A) Effect of proteasomal inhibitor lactacystin on LTR-
c reporter and 300 ng 61E-LTR or p65/relA expression plasmid by lipofectamine
ells along with DNA-lipofectamine mixture. Cells were harvested 24 h post-
-3T3 cells transfected with 61E-LTR or pTZ19 similarly as in Fig. 2A but instead
Western immunoblotting. Same blots were later analyzed for h-actin. (C) Effect
0 ng 3XKB-luc reporter and 300 ng 61E-LTR and various amounts of dn-InB
1. Cells were harvested 24 h post-transfection for luciferase assay. (D) Effect of
-luc reporter and 61E-LTR along with expression plasmids for dominant negative
for luciferase assay.
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LTR expression as reported in Fig. 2A. This result thus
demonstrated that LTR expression leads to InB-a degradation,
which facilitates subsequent translocation of p65 to the nucleus.
To determine whether NFnB activation by the LTR requires
phosphorylation of the inhibitory protein InB, we conducted two
different experiments. First, we used a dominant negative form
of InB (dn-InB) that has serine to alanine mutation at positions
32 and 36, which prevent its phosphorylation, polyubiquitinyla-
tion and subsequent proteasomal degradation. Overexpression
of this dn-InB thus sequesters endogenous NFnB in the
cytoplasm, blocking its dissociation and translocation into the
nucleus. As shown in Fig. 4C, dn-InB expression strongly
inhibits LTR-mediated activation of NFnB-dependent reporter
3xKB-Luc in transient transfection experiments. In the second
approach, we inhibited the upstream kinase that phosphorylates
InB and determined how it affects LTR-mediated transactiva-
tion. In response to stimulation, InB is phosphorylated by InB-
kinase (IKK) complex. IKK complex is composed of two
kinases, IKKa, IKKh and another modulatory component
IKKg. Different external stimuli for activation of NFnB pathway
preferentially activate either IKKa or IKKh although they both
can phosphorylate InB. We used dominant negative forms of
IKKa (serine to alanine mutation at positions 176 and 180, dn-
IKK1) and IKKh (serine to alaninemutation at positions 177 and
181, dn-IKK2) which can interact with upstream regulators but
are unable to phosphorylate InB (Mercurio et al., 1997). As
shown in Fig. 4D, dn-IKK2 but not dn-IKK1, inhibits the ability
of the LTR to activate NFnB-dependent reporter. This result
collectively showed that phosphorylation of InB is necessary for
NFnB activation by the LTR.
Gene transactivation function of the LTR does not require new
protein synthesis
To determine if synthesis of any new protein is necessary for
NFnB activation by the LTR, we cotransfected 61E-LTR and
3XKB-luc reporter in Balb-3T3 cells as before but in the
presence or absence of the protein synthesis inhibitor cyclo-
heximide, and measured transactivation by luciferase assay. In
parallel, we analyzed transcription of the luciferase gene by
measuring luciferase mRNA production by RT-PCR analysis.
We chose two different concentrations of cycloheximide, 5 AM
for 18 h or 1 AM for 24 h. Both treatments of cycloheximide
inhibited >95% new protein synthesis in Balb-3T3 cells as
determined by 35S-methionine incorporation (data not shown).
As shown in Fig. 5A, cycloheximide at both 5 AM and 1 AM
concentrations almost completely inhibited LTR-mediated
activation of NFnB-dependent luciferase activity as expected,
demonstrating effective suppression of protein synthesis. In
untreated cells, however, 7-fold activation of luciferase reporter
by the LTR was observed, as in previous experiments. RT-PCR
analysis performed on the total RNA extracted from cyclohex-
imide untreated cells showed that there was a strong induction
of luciferase RNA expression in cells transfected with 61E-LTR
whereas no such induction was seen in cells transfected with
vector pTZ19 (Fig. 5B). Interestingly, presence of 1 AMcycloheximide did not inhibit induction of luciferase RNA
expression by the LTR. Similar result was also obtained with
cells treated with 5 AM cycloheximide (data not shown). PCR
performed on the same RNA samples without any reverse
transcription confirmed the absence of any contaminating
luciferase reporter DNA. The production of h-actin RNA was
similar in all samples irrespective of cycloheximide treatment.
This result demonstrated that new protein synthesis was not
required for LTR-mediated activation of NFnB.
We designed another experiment to determine the role of
new protein synthesis in transactivation by using dn-InB,
which strongly inhibits LTR-mediated activation of NFnB. We
reasoned that since protein synthesis is necessary for dn-InB-
mediated effect, dn-InB should not be able to inhibit LTR-
mediated luciferase RNA production in the presence of
cycloheximide. Result presented in Fig. 5C shows that
activation of the luciferase reporter activity by 61E-LTR, in
the presence of dn-InB, was abolished both in the presence and
in the absence of cycloheximide, as expected. RT-PCR
experiment showed that expression of dn-InB completely
inhibited LTR-mediated luciferase RNA production in the
absence of cycloheximide. However, luciferase RNA produc-
tion was detected in cycloheximide-treated cells cotransfected
with LTR and dn-InB, as predicted (Fig. 5D). These data
demonstrated further that new protein synthesis is not
necessary for transactivation. Further, complete inhibition of
luciferase RNA production by the LTR in presence of dn-InB
also suggested against any mechanism by which LTR may act
directly as a coactivator of gene transcription.
PKR/ MEFs support activation of NFjB by the LTR
RNA folding analysis indicated that LTR transcript can
assume stable stem–loop structure, making dsRNA-dependent
kinase PKR, a known activator of NFnB, a potential target in
the LTR-mediated transactivation process. To investigate
potential involvement of the PKR in this signaling cascade,
we analyzed the activation of NFnB-dependent reporter by the
LTR in PKR/ MEFs and compared to normal PKR+/+ MEFs
and Balb-3T3 cells. We verified the status of PKR protein in
these cells by Western blot analysis of whole cell lysates. As
expected, PKR/ MEFs did not express PKR, whereas the
other two cell lines did express the protein (Fig. 6A). Next, we
cotransfected these three cell lines with wild-type or mutant
U3-LTR (61E-LTR or EDD2), full-length virus (61E or 61E-
Mut) or pTZ19 vector and 3XKB-Luc and measured luciferase
activity in the cell lysates 48 h after transfection. Cells were
also transfected with 100 ng of green florescence protein in
separate wells to compare transfection efficiency. As shown in
Fig. 6B, even in the absence of PKR expression, 61E-LTR was
able to activate the NFnB reporter, and the level of induction
(6–8-fold) was comparable to that seen in either PKR+/+ MEFs
and Balb-3T3 cells (as shown in Fig. 3). Comparison of GFP
expression in these three cells showed that transfection
efficiency in PKR/ cells was 40–50%, compared to 25–
30% in Balb-3T3 cells and 15–20% in PKR+/+ MEFs. Lower
transfection efficiency in PKR+/+ MEFs compared to PKR/
Fig. 5. New protein synthesis is not necessary for LTR-mediated gene transactivation. (A) Effect of cycloheximide on the activation of NFnB-dependent luciferase
reporters by the LTR. Cotransfection experiments were carried out with 3XKB-luc reporter and 61E-LTR or vector pTZ19 plasmid in Balb-3T3 cells by lipofectamine
plus method. Cycloheximide (5 AMor 1AMCHX) was added to cells in appropriate wells 30 min after the DNA-lipofectamine complex was added onto the cells. Cells
were harvested for luciferase assay at 18 h (for 5 AMCHX treatment) or 24 h (for 1 AMCHX treatment) post-transfection. (B) Effect of cycloheximide on transcription of
luciferase reporter gene by the LTR. Total cellular RNA (2 Ag) from a second set of Balb-3T3 cells cotransfected and cycloheximide-treated essentially similarly as
above, were subjected to RT-PCR analysis for luciferase mRNA. RT-PCR figure shows data for 24 h treatment group only. Essentially similar results were obtained with
18 h treatment group. In order to demonstrate absence ofDNA contamination in RNApreparations, one set of PCR amplification for each samplewas carried out without
any RTand loaded onto the lanes marked as F_. All RNA samples were also tested for h-actin mRNA byRT-PCR performed in similar manner as for luciferase mRNA.
Lane C represents PCR control with no RNA sample. Products were separated on 2% agarose gel. The 100 bp DNA ladder was included in the left lane. The amplified
product for luciferase mRNA (250 bp) and h-actin mRNA (353 bp) are indicated by an arrow. (C) Effect of cycloheximide on the inhibitory effect of dn-InB. Balb-3T3
cells were cotransfected with 3XKB-luc reporter and 61E-LTR or vector pTZ19 plasmid as above. In addition, somewells were also cotransfected with 200 ng of dn-InB
as indicated. One set of LTR and LTR + dn-InB transfected cells were treated with 1 AM cycloheximide. Cells from all transfected wells were harvested at 24 h post-
transfection for luciferase assay. (D) Effect of cycloheximide and dn-InB on transcriptional activation of luciferase reporter gene by the LTR. Total cellular RNA from a
similar set of transfected cells as in section C were subjected to RT-PCR analysis for luciferase and h-actin mRNA essentially as described in section B.
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These results demonstrated that PKR is not necessary for
NFnB activation by the LTR.
TLR3 acts as an intermediate in LTR-mediated signaling
As an alternate mechanism of activation of RNA-mediated
signaling event, we looked into the possibility that LTR may
activate TLR signaling. TLRs are an integral part of cellular
innate immune response, which are activated by various
extracellular ligands of microbial origin including dsRNA,
single stranded RNA (ssRNA), lipopolysaccharides and CpG
DNA (Kawai and Akira, 2005; Takeda et al., 2003). Activation
of these receptors initiates a number of complex signaling
cascades leading to activation of both NFnB and MAPK
pathways. Of the 11 members of the TLR family identified to
date, TLR3, TLR7 and TLR8 are activated by RNA molecule(Heil et al., 2004). However, dsRNA is the primary activator for
TLR3 (Alexopoulou et al., 2001). Although, TLRs are primarily
cell surface molecules, TLR3, -7, -8 and -9 are also retained in
endocytic compartment (Heil et al., 2003). To test whether TLR3
signaling is activated by the LTR, we tested HEK293 cells
(which are negative for all TLR expression) and HEK293 cells
stably expressing mouse-TLR3 for their ability to transactivate
gene expression. As shown in Fig. 6C, parental HEK293 cells
did not support activation of NFnB-dependent reporter expres-
sion by 61E-LTR but HEK293 that expresses m-TLR3
(HEK293/m-TLR3) strongly activated expression of the report-
er. Transfection of p65 expression plasmid in both cells resulted
in huge activation of the reporter in both cell types suggesting
that the failure of reporter activation in HEK293 cells by the LTR
is due to the absence of TLR3 and not because of transfection
efficiency. That HEK293/m-TLR3 cells were really expressing
m-TLR3 was verified by the fact that synthetic dsRNA polyI:C
Fig. 6. Role of PKR and TLR3 in the activation of NFnB by the LTR. (A) Analysis of PKR expression in the cell lines used in this study. Whole cell lysates (15 Ag total
protein) from actively growing Balb-3T3, PKR+/+ or PKR/MEFs were separated on 10% SDS-PAGE, and Western immunoblotting analysis was performed using
polyclonal anti-PKR serum. Lysates were also analyzed in separate SDS-PAGE for h-Actin using specific monoclonal antibody. (B) Analysis of NFnB-dependent
reporter gene activation in PKR/ cells. PKR/ and PKR+/+ cells were cotransfected by lipofectamine plus method with 100 ng 3XKB-luc and 300 ng of either wild-
type (b) or mutant (c) FeLV U3-LTR constructs (61E-LTR or EDD2, respectively), wild-type (d) or mutant (e) full-length FeLV constructs (61E or 61E-Mut,
respectively) or pTZ19 vector plasmid (a). Cells were harvested for luciferase assay 48 h after transfection. As a control, same set of transfection was also carried out on
Balb-3T3 cells as in Fig. 3B. (C) Role of TLR3 in the activation of NFnB pathway by the LTR. TLR deficient regular HEK293 cells and HEK293 cells stably expressing
mouse TLR3 (from Invivogen) were cotransfected by lipofectamine plus method with 100 ng of 3XKB-Luc reporter and 300 ng of pTZ19 vector, 61E-LTR or p65
expression plasmid as indicated. Synthetic dsRNApolyI:C (100 Ag/ml) or loxoribine (1 AM)was added to themedia 8 h before harvesting the cells for luciferase assay at
24 h post-transfection.
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HEK293 cells. Synthetic agonist for ssRNA-activated TLR7 and
TLR8, loxoribine, however, failed to activate reporter similarly
in either cell lines. These results strongly suggested that TLR3-
mediated signaling is involved in LTR-mediated activation of
NFnB-dependent genes.
Ras plays a role in NFjB activation by the LTR
We have previously demonstrated that inhibitor of MEK1/2
abrogates collagenase IV gene transactivation by the LTR
which suggested a necessary role of MAPK pathway in the
process. To determine whether NFnB activation is required forupregulation of MAPK pathway by the LTR, we tested the
effect of expression of dn-InB (which inhibits NFnB activa-
tion) on LTR-mediated activation of collagenase IVand MCP-1
genes. In transient transfection assays, dn-InB was cotrans-
fected with 517 coll-CAT or MCP-1-CAT and 61E-LTR in
Balb-3T3 cells. As shown in Fig. 7A, dn-InB strongly inhibited
activation of NFnB by the LTR as expected, but not of
collagenase IV or MCP-1 gene expression. These data
demonstrated that activation of NFnB is not necessary for
collagenase IV or MCP-1 gene upregulation by the LTR.
Since upstream regulators of MAPK pathway such as Ras
and Raf have been shown to activate NFnB signaling, we
wanted to test if they have any role in the NFnB activation by
Fig. 7. Analysis of upstream signaling pathways leading to the activation of
NFnB by the LTR. (A) Inhibition of NFnB activation does not affect
collagenase IV and MCP-1 activation by the LTR. Balb-3T3 cells were
cotransfected with 517coll-CAT, NFBCO-CAT or MCP-1-CAT together with
pTZ19 vector or 61E-LTR and dn-InB as described in Fig. 1A. (B) Analysis of
role of Ras-Raf-MAPK pathway in NFnB activation. Balb-3T3 cells were
cotransfected with 3XKB-luc and 61E-LTR or pTZ19 vector along with
inhibitors as indicated. The dominant negative Ras (RasN17) and dnRaf-1 (Raf-
BXB-K375W) constructs were used at 300 ng per well. The MEK1/2 inhibitor
PD98059 (50 AM) was added to the cells in appropriate wells along with DNA-
lipofectamine mixture.
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regulators of Ras-Raf-MAPK pathway for their ability to
abrogate LTR-mediated NFnB activation. We cotransfected
61E-LTR and 3XKb-Luc reporter along with dominant negative
Ras (N17-Ras) or dominant negative Raf-1 (dnRaf-1/Raf-BXB-
K375W), or treated the cells with MEK1/2 inhibitor PD98059.
As shown in Fig. 7B, both N17-Ras and dnRaf-1 strongly
inhibited LTR-mediated activation of 3XKB-Luc reporter. On
the other hand, PD98059 only had a modest effect on inhibiting
3XKB-Luc reporter. These data demonstrated that functional
Ras and Raf-1 are necessary for NFnB activation by the LTR.
However, inability of PD98059 to block such activity effec-
tively suggested that LTR does not require active MAPK for
activating NFnB-dependent gene expression.Discussion
In this study, we demonstrated that the U3-LTR region of
FeLV activates NFnB-dependent gene expression. Previous
studies have shown that insertion of unrelated sequences into
the leukemia virus U3-LTR region leads to a defect in
preleukemic events in pathogenesis such as hematopoietic hy-
perplasia and production of recombinant mink cell focus-
inducing viruses but without affecting virus replication and
spread (Brightman et al., 1993). This suggested that U3-LTR
might influence target cell growth by some mechanism intrinsic
to LTR. We have previously demonstrated that the U3-LTR
region of Mo-MuLV and FeLV can transactivate expression of
specific cellular genes and this activity correlated with the ability
of the LTR to make specific RNA transcript (Ghosh and Faller,
1999; Ghosh et al., 2000). In this study, we investigated whether
this transactivating property of the LTR might function through
activation of NFnB. Further, we focused on NFnB signaling
pathway because it can be activated by dsRNA and could po-
tentially mediate the induction of many of the host genes regu-
lated by the LTR. Although NFnB is an important regulator of
host immune response against a variety of external stimuli, its
role in various cancers has also been described. Reticuloen-
dotheliosis virus encoded Rel protein, whose cellular counter-
part c-Rel is a member of NFnB complex, causes lymphoid
tumors in chickens (Chen et al., 1983; Wilhelmsen et al., 1984).
Further, the genes for c-Rel, NFnB2 (p100/52) and Bcl-3
proteins, all members of NFnB complex, are located within
regions of chromosomes that are often involved in rearrange-
ment or deletion (Fracchiolla et al., 1993; McKeithan et al.,
1997; Rayet and Gelinas, 1999). NFnB is also known to ac-
tivate genes that are involved in the control of cell growth
and apoptosis. Antiapoptotic genes such as Bcl-2 family
members (Bcl-XL and A1/Bfl-1), cellular inhibitors of apo-
ptosis (c-IAP and IXAP) and TRAFs or genes such as cyclin
D1 which promote cell cycle progression, can be directly
activated by NFnB and thus facilitate tumorigenesis (Gut-
tridge et al., 1999; Wang et al., 1998, 1999; Wu et al., 1998).
In fact, many tumor cell lines express high level of NFnB in the
nucleus and conversely, inhibition of NFnB expression in
many transformed cells induces apoptosis (Sovak et al., 1997;
Wang et al., 1996). Thus, our finding that the LTR alone can
activate the NFnB pathway is significant and suggests that this
activation could be a mechanism by which LTR may exert cell
proliferative activity.
NFnB is activated by various external stimuli, including
growth factor and mitogens, stress-inducing agents, cytokines,
bacterial lipopolysaccharides and viral infection. The signaling
pathways activated by these stimuli are diverse and include a
variety of secondary signal transducer molecules such as TNF-
a receptor-associated factors (TRAFs), NFnB-inducing kinase
(NIK), TLRs, TGF-h-activated kinase (TAK1), MAPK kinase
kinase 1 (MEKK1), protein kinase C and PKR (Karin and Lin,
2002; Yamamoto and Gaynor, 2004). Most of these signaling
molecules ultimately activate IKK. Although phosphorylation
of InB by IKK and its subsequent proteasomal degradation
followed by nuclear translocation of dimeric NFnB are the
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atypical pathways have also been described. NFnB activation
by hypoxia treatment or UV radiation does not involve InBa
phosphorylation at serine 32 and 36 (Imbert et al., 1996; Li
and Karin, 1998). In our experiments, the super-repressor dn-
InB completely abrogated LTR-mediated NFnB activation,
indicating that InBa phosphorylation at position 32 and 36
was required and no atypical method of activation was
involved. Similarly, the ability of lactacystin to inhibit LTR-
mediated transactivation, as shown in Fig. 4, indicated that
proteasomal activity is also an integral part of this transactiva-
tion process. Transactivation experiments with dominant-
negative IKKs demonstrated that IKKh is specifically required
for NFnB activation by the LTR, linking it to the same
pathway as that activated by proinflammatory cytokines (Li et
al., 1999; Sizemore et al., 2002; Tanaka et al., 1999).
The central importance of NFnB activation in cellular
physiology has made it an attractive target for viruses and
many viruses have developed various strategies to alter the
NFnB signaling pathway. In most of these strategies, virus-
encoded proteins interact with different signaling molecules
that ultimately activate IKK. For example, EBV latent
membrane protein (LMP1), HCV core protein, rotavirus VP4
protein, HBV HBx protein, HTLV-1 tax protein, HIV gp120
and tat protein and influenza virus proteins can all activate IKK
(Cahir-McFarland et al., 2000; Demarchi et al., 1999; Flory et
al., 1998, 2000; Harhaj and Sun, 1999; Kim et al., 2001;
LaMonica et al., 2001; Sylla et al., 1998; You et al., 1999). On
the other hand, measles virus and vesicular stomatitis virus-
mediated activation of NFnB has been attributed to cellular
PKR activation possibly by viral RNA molecules (Donze et al.,
2004). A recent comprehensive review of various pathways to
modulate NFnB activity employed by viruses is available
(Santoro et al., 2003). We demonstrated in this report that the
full-length wild-type FeLV, but not the virus with a mutation in
U3-LTR, can activate NFnB. We also demonstrated that
activation of NFnB-dependent gene expression by the LTR
takes place in the absence of any new protein synthesis. We
have previously demonstrated a causal relationship between
transcript production and transactivational ability of the LTR
(Ghosh et al., 2000). Taken together, our data show that NFnB
activation by FeLV is an RNA-mediated event.
Several studies have implicated an essential role of PKR in
the activation of NFnB by dsRNA. For example, dsRNA has
been shown to activate NFnB binding to the h-interferon
promoter in many different cell lines and the nucleoside analog
2-aminopurine (2-AP), a PKR inhibitor, blocked such activity
(Visvanathan and Goodbourn, 1989). Further, selective degra-
dation of PKR RNA in HeLa cells by antisense oligonucleotide
also inhibited dsRNA-mediated activation of NFnB (Maran et
al., 1994). Synthetic dsRNA (pI:C)-mediated activation of
NFnB was also perturbed in PKR/ cells, suggesting further
the role of PKR in the process (Yang et al., 1995). In other
experiments, IKKh has been shown to be essential for PKR-
mediated signaling in response to dsRNA or vesicular
stomatitis virus (Chu et al., 1999). Possible involvement of
LTR transcript and requirement of IKKh for NFnB activationin our study thus suggested that PKR could be involved in the
process. However, by using PKR/ MEFs, we demonstrate
here that LTR-mediated activation of NFnB is independent of
PKR activity. Two previous studies demonstrated that such
PKR-independent alternate dsRNA-dependent NFnB activa-
tion pathways indeed exist. One such study demonstrated that
dsRNA-mediated activation of h-IFN and inflammatory
cytokine does not require PKR or RNase-L (Iordanov et al.,
2001). In another study, both PKR-dependent and -independent
pathways have been demonstrated for dsRNA-mediated
activation of macrophages (Maggi et al., 2000). Furthermore,
it has been shown that PKR is not required for dsRNA-induced
NFnB activation in rat islets (Blair et al., 2001).
Several recent studies demonstrated that association of
TLRs with their specific ligands activates both NFnB and
MAPK pathways (Kawai and Akira, 2005; Wang et al., 2001).
Various virus-associated molecular patterns such as, dsRNA,
ssRNA, CpG DNA and envelope glycoproteins have already
been reported to be the targets of various TLRs (Boehme and
Compton, 2004). Our demonstration that TLR3 is required for
LTR-mediated activation suggests that LTR transcript is
another member of these targets. Most importantly, the
necessity of TLR3 in NFnB activation by the LTR suggests
that this could be the missing link between LTR transcript and
cellular gene transactivation.
Since LTR also activates other cellular genes such as
collagenase IV and MCP-1, and there are evidences that NFnB
canmodulate their expression (Takeshita et al., 1999; Ueda et al.,
1997), it was possible that NFnB acts a mediator for their
upregulation in LTR expressing cells. But we could not
demonstrate any effect of dn-InB on the LTR-mediated
expression of collagenase IV or MCP-1. However, our studies
with dominant negative forms of MAPK pathway members
showed that, in fact, Ras and Raf-1 act as upstream regulators of
NFnB signaling by the LTR. Ras and Raf-1 have been
previously shown to activate NFnB (Arsura et al., 2000;
Baumann et al., 2000; Finco and Baldwin, 1993). Rat liver
epithelial cells transformed with oncogenic Ras or Raf show
upregulation of NFnB and this activity could be inhibited by the
expression of dn-IKK1 or dn-IKK2. Specifically, dn-IKK2 was
more potent in inhibiting Raf-induced NFnB activation in Raf-
transformed cells, whereas both Raf- and PI3-kinase-mediated
pathways were involved in Ras-transformed cells and both IKK1
and IKK2 were necessary for the latter. In our system, RasN17,
Raf-BXB-K375W and dn-IKK2 (but not dn-IKK1) inhibited
LTR-mediated activation of NFnB. This suggested a Ras-Raf-
IKK-InB pathway of NFnB activation. Our finding of Ras as an
upstream regulator of LTR-mediated cellular gene transactiva-
tion is consistent with our previous finding which demonstrated
that MEK1/2 inhibitor PD98059 inhibits activation of collage-
nase IV gene expression by the LTR (Ghosh and Faller, 1999). It
is therefore conceivable that both NFnB and MAPK activation
by the LTR acts in synergy in disease pathogenesis.
Data presented in this report also suggest a mechanism by
which both NFnB as well as MAPK pathway can be activated
following interaction of LTR transcript with TLR3. Such
association could lead to activation of Ras as has been
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(Yeo et al., 2003). Activated Ras subsequently initiates Ras-
Raf-IKK-InB signaling cascade that liberates NFnB, facilitat-
ing its translocation to the nucleus and ultimately enhances
NFnB-dependent gene expression. Activated Ras and Raf can
also independently upregulate MAPK signaling pathway.
Materials and methods
Cells
Balb-3T3 and HEK293 cells were obtained from American
Type Culture Collection and maintained in DMEM containing
penicillin (100 U/ml) and streptomycin (100 Ag/ml) with 10%
donor calf serum or fetal calf serum, respectively, at 37 -C in a
humidified incubator under 5% CO2. Wild-type and PKR-neg-
ative mouse embryo fibroblasts (MEF) (PKR+/+ and PKR/,
respectively) were provided by B. Williams from the Cleveland
Clinic Foundation and were maintained in DMEM containing
10% fetal calf serum and antibiotics. HEK293 cells stably
expressing mouse TLR3 were purchased from Invivogen (San
Diego, CA) and maintained in DMEM containing 10% fetal calf
serum, penicillin, streptomycin and blasticidin (10 Ag/ml).
Plasmids
Replication competent FeLV full-length clone 61E and U3-
LTR construct 61E-LTR (which contain sequences from 307
to +34) have been described previously (Ghosh and Faller,
1999). Replication competent Mo-MuLV full-length clone
Mov9 and U3-LTR construct GMNX (which contain sequences
from 419 to 147) also have been described (Choi and
Faller, 1995). EDD2 is a derivative of 61E-LTR with 8 base
substitutions that abrogates its transactivational activity to-
wards collagenase IV promoter. 61E-Mut is a full-length FeLV
as 61E but has EDD2-specific mutations in both 5V- and 3V-
LTR. Both EDD2 and 61E-Mut have been described before
(Abujamra et al., 2003). The eukaryotic expression plasmid for
a ‘‘dominant negative’’ form of InB (dn-InB), also known as
super-repressor of NFnB, was provided by M. Karin and
contains serine to alanine mutation at positions 32 and 36.
Dominant-negative forms of InB kinases, IKKa (dn-IKK1) and
IKKh (dn-IKK2) were gifts from G. Sonenshein. Dominant-
negative form of Ras (RasN17) and Raf-1 (Raf-BXB-K375W)
were obtained from G. Denis and C. Chen, respectively.
Reporter plasmids NFBCO-CAT, OBCO-CAT and 3XKB-Luc
were from T. Gilmore and PBIIx-Luc from S. Ghosh. All other
reporter constructs (517/+ 62 coll-CAT, 543 JE-CAT,
KbHN-MHC-CAT and IL-6-CAT) have been described in our
previous work (Ghosh and Faller, 1999). Plasmid pTZ19 is a
2.86 kb cloning vector from United States Biochemicals.
Transfection and reporter assays
Actively growing cells were transfected with CsCl purified
plasmids by either the DEAE-dextran method as described
previously (Ghosh and Faller, 1999) or by Lipofectamine Plusreagent (Invitrogen) according to manufacturer’s protocol. For
chloramphenicol acetyl transferase (CAT) assays, cells were
harvested at indicated times and lysed by quick freezing and
thawing three times. Equal amounts of protein from clarified
supernatant fractions were then assayed for CAT activity using
14C-Chloramphenicol and acetyl-CoA, followed by chromato-
graphic separation of acetylated 14C-chloramphenicol. For
luciferase assays, cells were washed once in PBS and lysed on
the plate using cell culture lysis reagent (Promega). To ensure
complete lysis, harvested lysate was subjected to rapid freezing
and thawing once. Clarified supernatant was then used for
luciferase assay using assay reagents from Promega in a TD-20/
20 luminometer (Turner Designs). Transfection efficiency was
monitored by cotransfection of either 1 Ag (for DEAE-dextran
transfection) or 0.1 Ag (for lipofectamine plus transfection) of an
expression plasmid for green fluorescence protein (EGFP) from
Stratagene. In some transfection experiments, Lactacystin
(Clasto-Lactacystin h-lactone, Calbiochem), cycloheximide
(Sigma Chemicals), PD98059 (Calbiochem), polyI:C (Sigma
Chemicals) or Loxiribine (Invivogen) was used as described in
the Results section and figure legends. All transfection experi-
ments were repeated at least three times and standard deviations
were determined from these replicates.
RT-PCR
Analysis of requirement for new protein synthesis during
gene transactivation was performed by RT-PCR. RNA was
extracted from various transfected cells, untreated or treated with
cycloheximide. Cells were washed once with PBS, harvested
and total cellular RNAwas extracted by Trizol extractionmethod
according to manufacturer’s protocol (Invitrogen). All RNA
preparations were digested with RQ1-RNase free DNase
(Promega) at a concentration of 0.1 unit/Al, followed by
phenol-chloroform extraction, ethanol precipitation and suspen-
sion in DEPC-treated water. DNase digestions were repeated to
ensure complete removal of any contaminating DNA. First
strand cDNA synthesis for luciferase and h-actin mRNA was
performed on 2 Ag of total RNA at 50 -C using Thermoscript
cDNA synthesis kit (Invitrogen). Antisense primers used for
reverse transcription had the following sequences: 5V-
ATAAATGTCGTTCGCGGGCG-3V(luciferase) and 5V-CAAA-
CATGATCTGGGTCATCTTCTC-3V(h-actin). One-twentieth
fraction of the RT product was used in PCR reactions (30 s
denaturation at 94 -C, 1 min annealing at 55 -C and 1 min
extension at 72 -C) using antisense primers as above and
following sense primers: 5V-GCATAAGGCTATGAAGAGAT-
3V(luciferase) and 5V-GCTCGTCGTCGACAACGGCTC-3V (h-
actin). RNA samples without any reverse transcription were
used as a negative control in all PCR reactions. In order to
maintain a linear range during amplification, PCR was carried
out for only 25 cycles.
Nuclear extracts
Cells were harvested by scraping, washed once with PBS
and twice with hypotonic buffer (10 mM HEPES, pH 7.9; 1.5
A.L. Abujamra et al. / Virology 345 (2006) 390–403 401mM MgCl2; 10 mM KCl) at 4 -C. Cells were then allowed to
swell in the presence of 1 ml hypotonic buffer (per 107 cells)
for 20 min on ice. Cells were harvested and resuspended in 0.4
ml hypotonic buffer containing 0.5 mM DTT, 0.5 mM PMSF, 1
Ag/ml aprotinin and 0.2% NP-40 and left on ice for another 5
min. Cytoplasmic membrane was disrupted by vortexing
vigorously for 30 s and the nuclei were pelleted by high speed
centrifuge at 4 -C for 20 s. Nuclei were suspended in high salt
extraction buffer (20 mM HEPES, pH 7.9; 1.5 mM MgCl2; 420
mM NaCl; 0.5 mM DTT; 0.5 mM PMSF; 1 Ag/ml aprotinin;
25% glycerol) and incubated for 30 min on ice for nuclear
proteins to leach out. The nuclear extract was clarified by
centrifugation in microfuge for 10 min at 4 -C.
Immunoblotting
Whole cell extracts (WCE) were prepared in RIPA buffer
(25 mM Tris–HCl, pH 7.5; 150 mM NaCl; 0.1% SDS; 1.0%
sodium deoxycholate; 1.0% Triton X-100) containing protein-
ase inhibitor cocktail from Roche. Twenty micrograms of
nuclear extract or WCE was separated on a 10% SDS-
polyacrylamide gel and transferred electrophoretically to a
nitrocellulose membrane. Membranes were blocked with 5%
nonfat dry milk in PBS containing 0.05% Tween-20 and were
incubated overnight with the following antibodies as appropri-
ate: rabbit polyclonal anti-p65/RelA (Santa Cruz sc-372), anti
InB-a (Santa Cruz sc-371), anti-PKR (Santa Cruz sc-708),
mouse monoclonal anti-PCNA (Santa Cruz sc-56) and anti-h-
actin (Oncogene CP01). Goat anti-rabbit or anti-mouse IgG
conjugated to horseradish peroxidase (Oncogene) was used as
secondary antibody. Bound antibodies were detected by
Western Lightning Chemoluminescence kit (PerkinElmer Life
Sciences). Prestained molecular weight protein markers
(Benchmark marker, Invitrogen) were used to determine
molecular weight of the detected bands.
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